BR112019024509A2 - Glicuronídeo de pró-fármacos dos inibidores da janus quinase - Google Patents

Glicuronídeo de pró-fármacos dos inibidores da janus quinase Download PDF

Info

Publication number
BR112019024509A2
BR112019024509A2 BR112019024509-0A BR112019024509A BR112019024509A2 BR 112019024509 A2 BR112019024509 A2 BR 112019024509A2 BR 112019024509 A BR112019024509 A BR 112019024509A BR 112019024509 A2 BR112019024509 A2 BR 112019024509A2
Authority
BR
Brazil
Prior art keywords
methyl
compound
mmol
pct
pyran
Prior art date
Application number
BR112019024509-0A
Other languages
English (en)
Portuguese (pt)
Inventor
D. Long Daniel
Daniel D. Long
A.A. Wilton Donna
Donna A.A. Wilton
Loo Mandy
Mandy LOO
Hudson Ryan
Ryan Hudson
J. Brassil Patrick
Patrick J. Brassil
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112019024509A2 publication Critical patent/BR112019024509A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112019024509-0A 2017-05-23 2018-05-22 Glicuronídeo de pró-fármacos dos inibidores da janus quinase BR112019024509A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509847P 2017-05-23 2017-05-23
US62/509,847 2017-05-23
PCT/US2018/033818 WO2018217700A1 (en) 2017-05-23 2018-05-22 Glucuronide prodrugs of janus kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019024509A2 true BR112019024509A2 (pt) 2020-06-23

Family

ID=62621001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024509-0A BR112019024509A2 (pt) 2017-05-23 2018-05-22 Glicuronídeo de pró-fármacos dos inibidores da janus quinase

Country Status (14)

Country Link
US (2) US10745405B2 (https=)
EP (1) EP3609899A1 (https=)
JP (1) JP2020520955A (https=)
KR (1) KR20200010440A (https=)
CN (1) CN110662747A (https=)
AU (1) AU2018273866B2 (https=)
BR (1) BR112019024509A2 (https=)
CA (1) CA3063963A1 (https=)
IL (1) IL270693A (https=)
MX (1) MX2019014054A (https=)
NZ (1) NZ759764A (https=)
PH (1) PH12019502605A1 (https=)
RU (1) RU2019142472A (https=)
WO (1) WO2018217700A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111196831B (zh) * 2020-01-20 2023-05-09 山西医科大学 一种呋喃酚葡萄糖醛酸结合物的制备方法
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
EP4384173A1 (en) * 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
CN119923257A (zh) * 2022-04-15 2025-05-02 密歇根大学董事会 Jak抑制剂类似物、制剂及其用途
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
EP4637724A1 (en) 2022-12-22 2025-10-29 KRKA, d.d., Novo mesto Veterinary composition comprising oclacitinib
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) * 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
US7798257B2 (en) 2004-04-30 2010-09-21 Smith International, Inc. Shaped cutter surface
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ[2,3−d]ピリミジン化合物
KR101921850B1 (ko) * 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
JP2013518882A (ja) 2010-02-05 2013-05-23 ファイザー・インク JAK阻害剤としてのピロロ[2,3−d]ピリミジン尿素化合物
JP2016528174A (ja) 2013-05-31 2016-09-15 セルリアン・ファーマ・インコーポレイテッド 治療的送達用のシクロデキストリンベースのポリマー
ES2784523T3 (es) 2015-11-24 2020-09-28 Theravance Biopharma R&D Ip Llc Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales
CN106496233B (zh) * 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
WO2018217700A1 (en) 2018-11-29
US10745405B2 (en) 2020-08-18
MX2019014054A (es) 2020-02-05
US20180339990A1 (en) 2018-11-29
RU2019142472A3 (https=) 2021-09-23
AU2018273866B2 (en) 2021-09-30
NZ759764A (en) 2022-07-01
EP3609899A1 (en) 2020-02-19
CA3063963A1 (en) 2018-11-29
US20210032250A1 (en) 2021-02-04
JP2020520955A (ja) 2020-07-16
IL270693A (en) 2020-01-30
CN110662747A (zh) 2020-01-07
PH12019502605A1 (en) 2020-10-26
AU2018273866A1 (en) 2019-12-19
RU2019142472A (ru) 2021-06-24
KR20200010440A (ko) 2020-01-30

Similar Documents

Publication Publication Date Title
BR112019024509A2 (pt) Glicuronídeo de pró-fármacos dos inibidores da janus quinase
US10472366B2 (en) Glucuronide prodrugs of tofacitinib
CN113811300B (zh) Tead转录因子的新型小分子抑制剂
CN109963844B (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
JP6778747B2 (ja) 胃腸炎症性腸疾患の処置のための、jak阻害剤化合物のプロドラッグ
ES2489645T3 (es) Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión
EP4549442A1 (en) Prmt5 inhibitors and use thereof
US10562864B2 (en) Chemical modulators of immune checkpoints and therapeutic use
CA2942975A1 (en) Substituted acrylamide and substituted ethenesulfonamide derivatives and pharmaceutical compositions thereof useful as amyloid targeting agents
TWI393708B (zh) 異羥肟酸脂化合物,其用途及其之合成方法
KR20140040104A (ko) 대사 및 염증 질병의 치료에 유용한 아제티딘 유도체
RS66733B1 (sr) Inhibitori alfa v beta6 integrina
CA3151776C (en) Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof
AU2015298476B2 (en) Benzodiazepine derivatives as CCK2/gastrin receptor antagonists
AU2020410900B2 (en) Compound used as RET kinase inhibitor and application thereof
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
JP6298172B2 (ja) Gpr142アゴニスト化合物
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ
WO2016064682A1 (en) Selective inhibitors of constitutive androstane receptor
KR20170073699A (ko) 신규한 유형의 시티딘 유도체 이량체 및 그의 용도
EP4631931A1 (en) Hdac inhibitor and use thereof
CN118772107A (zh) Hdac抑制剂及其用途
CN121293163A (zh) 一种2-氨基苯基嘧啶衍生物及其制备方法与医药用途
WO2022203267A1 (ko) 아데노신 a2a 수용체 및 아데노신 a2b 수용체의 이중 길항제, 및 이의 용도
CN116332928A (zh) 嘧啶并吡啶酮类化合物及其应用

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements